Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763752 | 0.88 | KIF11 (0.58) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL764680 | 0.85 | KIF11 (0.63) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL763427 | 0.84 | KIF11 (0.64) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL764780 | 0.82 | KIF11 (0.60) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL763487 | 0.81 | KIF11 (0.51) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL8402709 | 0.81 | KIF11 (0.58) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL764905 | 0.80 | KIF11 (0.53) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL764191 | 0.79 | KIF11 (0.56) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL3567485 | 0.79 | KIF11 (0.82) | KIF11TP53ABCG2LMNA | |
| SCHEMBL4924334 | 0.79 | LMNA (0.56) | KIF11TP53MAPTABCG2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, FLT4, KDR | KIF11 3727/4885TP53 784/4885MAPT 4436/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | KIF11 3352/4885TP53 448/4885MAPT 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.